Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-20 EDT			5-day change	1st Jan Change
2.47 ^USD	0.00%		-9.19%	-36.34%

06-10	HC Wainwright Cuts Price Target on Anixa Biosciences to $7 From $12, Maintains Buy Rating	MT
06-04	Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI

Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2020

January 07, 2021 at 04:16 pm

Anixa Biosciences, Inc. announced earnings results for the full year ended October 31, 2020. For the full year, the company announced operating loss was USD 9.978 million compared to USD 11.890 million a year ago. Net loss was USD 10.018 million compared to USD 11.647 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.59 a year ago.

Latest news about Anixa Biosciences, Inc.

HC Wainwright Cuts Price Target on Anixa Biosciences to $7 From $12, Maintains Buy Rating	06-10	MT
Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	06-04	CI
Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial	05-21	CI
Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	05-08	CI
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	04-18	CI
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-12	CI
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment	02-12	MT
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	01-23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	01-23	CI
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	01-23	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-16	CI
North American Morning Briefing : Stock Futures -2-	01-16	DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks	01-09	DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data	01-02	DJ
Anixa Biosciences Unveils 'Positive' Results From Phase 1 Trial of Breast Cancer Vaccine	12-07	MT
Transcript : Anixa Biosciences, Inc. - Special Call	12-06
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	12-06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	11-27	CI
Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board	23-10-23	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	23-10-13	CI
Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board	23-09-19	CI
Anixa Biosciences, Inc.(NasdaqCM:ANIX) added to S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Concerns About -2-	23-09-07	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-06	CI
Anixa Biosciences Starts Treatment of Third Patient in Clinical Trial of Ovarian Cancer Therapy; Shares Rise	23-08-28	MT

Chart Anixa Biosciences, Inc.

Duration

Period

More charts

Company Profile

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Companyâs vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.47 USD

Average target price

7 USD

Spread / Average Target

+183.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANIXA BIOSCIENCES, INC.	-36.34%	79.06M
MODERNA, INC.	+35.14%	51.51B
IQVIA HOLDINGS INC.	-7.43%	39.03B
LONZA GROUP AG	+35.88%	38.91B
CELLTRION, INC.	-10.62%	26.68B
ICON PUBLIC LIMITED COMPANY	+11.63%	26.13B
ALNYLAM PHARMACEUTICALS, INC.	-17.77%	19.91B
UNITED THERAPEUTICS CORPORATION	+40.52%	13.71B
MEDPACE HOLDINGS, INC.	+30.70%	12.38B
BIO-TECHNE CORPORATION	-3.41%	11.74B

Other Biotechnology & Medical Research